Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Alopecia areata (AA) is an autoimmune condition causing nonscarring hair loss, often challenging to treat in severe forms.
• Janus kinase inhibitors, like tofacitinib, represent a promising therapeutic avenue for AA.
• This study evaluates tofacitinib's efficacy and predictive factors for treatment response in a Saudi population.

Purpose of the Study:

• To assess the efficacy and safety of tofacitinib in treating severe alopecia areata in Saudi patients.
• To identify patient characteristics that predict therapeutic response to tofacitinib.
• To evaluate the patient response rate using the Severity of Alopecia Tool (SALT) score.

Main Methods:

• Prospective cohort study conducted across three medical centers in Riyadh, Saudi Arabia.
• Inclusion of 68 patients with alopecia areata.
• Assessment of hair loss and regrowth using the Severity of Alopecia Tool (SALT) score at baseline, 3, and 6 months.

Main Results:

• At 6 months, 62.2% of 45 evaluable patients achieved >50% improvement in SALT score.
• Higher baseline SALT scores were associated with a lesser degree of improvement.
• Previous systemic steroid use correlated with a diminished treatment response (P=0.015).
• Patients with AA showed a significantly better response compared to those with alopecia totalis or universalis.

Conclusions:

• Tofacitinib demonstrates significant efficacy in treating severe alopecia areata within the studied Saudi population.
• The treatment is well-tolerated and exhibits a favorable safety profile.
• Predictive factors for response, such as baseline disease severity and prior treatments, warrant further investigation.